about
Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markersImprovement of Psychotic Symptoms and the Role of Tissue Plasminogen ActivatorCircadian influences on myocardial infarctionPlasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies.Dysfunction in the coagulation system and schizophreniaRedox-induced Src kinase and caveolin-1 signaling in TGF-β1-initiated SMAD2/3 activation and PAI-1 expressionHyperlipidaemia impairs the circadian clock and physiological homeostasis of vascular smooth muscle cells via the suppression of Smarcd1Arterial embolism caused by large mobile aortic thrombus in the absence of atherosclerosis, associated with iron deficiency anemia.Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization.A Phytochemical-rich Multivitamin-multimineral Supplement Is Bioavailable and Reduces Serum Oxidized Low-density Lipoprotein, Myeloperoxidase, and Plasminogen Activator Inhibitor-1 in a Four-week Pilot trial of Healthy Individuals.Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments.Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.Double-stranded DNA induces a prothrombotic phenotype in the vascular endothelium.Day/Night rhythm of hemostatic factors in obstructive sleep apnea.Circadian rhythms and metabolic syndrome: from experimental genetics to human disease.Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjectsIncreased Serum PAI-1 Levels in Subjects with Metabolic Syndrome and Long-Term Adverse Mental Symptoms: A Population-Based StudyApoE-/- PGC-1α-/- mice display reduced IL-18 levels and do not develop enhanced atherosclerosis.Inflammatory markers and obstructive sleep apnea in obese children: the NANOS study.Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.Arsenic Exposure and Subclinical Endpoints of Cardiovascular Diseases.Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral headPlatelets and their chemokines in atherosclerosis-clinical applications.Problem behavior of dementia patients predicts low-grade hypercoagulability in spousal caregivers.Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice.The orphan nuclear receptor Rev-erb alpha regulates circadian expression of plasminogen activator inhibitor type 1.Plasminogen activator inhibitor-1 inhibits factor VIIa bound to tissue factor.Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels.Elevated cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus.PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis.Iodixanol Has a Favourable Fibrinolytic Profile Compared to Iohexol in Cardiac Patients Undergoing Elective Angiography: A Double-Blind, Randomized, Parallel Group Study.Ways of coping and biomarkers of an increased atherothrombotic cardiovascular disease risk in elderly individualsEffect of Alzheimer caregiving on circulating levels of C-reactive protein and other biomarkers relevant to cardiovascular disease risk: a longitudinal studyEnhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions.Fibrinolytic activity and platelet function in subjects with obstructive sleep apnoea and a patent foramen ovale: is there an option for prevention of ischaemic stroke?Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster?Cardiovascular Risk in Children and Adolescents with Type 1 and Type 2 Diabetes Mellitus.Effect of continuous positive airway pressure on day/night rhythm of prothrombotic markers in obstructive sleep apnea.Association of ambulatory heart rate and atherosclerosis risk factors with blood pressure in young non-hypertensive adults
P2860
Q24644869-681FAFAC-1BA9-47C2-B3CC-07FA9231B3D6Q26828527-A6939471-47EF-43B7-9DC4-C3B7C59A99A9Q27008917-4AAEF725-AC0E-48B0-9225-45DF6B45244EQ27322768-0E1E0404-ACE6-44F2-A30F-6CBB1BC576ABQ28068412-09C5B501-C2F1-4B79-9779-BE661BFDDD98Q28512285-6F523D1F-CF0E-4B0C-BF5D-82AE149236BBQ28569433-3B3B28F6-8845-47A2-BDD4-10E0D5F29B3AQ30538407-9AB88FCB-B4C1-45CC-870E-B5DF18F82510Q33248476-62E1BB3B-C8FE-43D4-BA92-C46E47A05952Q33269618-A6BD6366-9915-4513-BCBF-AF987139DEECQ33570079-114109D8-832D-4483-9799-F8E376B82544Q33645678-605BE69B-708E-43D1-B36F-23C4E2385D82Q33652707-E35ED0E3-D26A-4E4D-9A35-656D9917D7EAQ33682822-5CF15DDF-8DC3-4599-81F7-6988031240B6Q33700780-0896C137-27EB-4D05-B0DC-18E6FCF72931Q33722806-625A4EA3-35A1-4C04-9724-468D0D47B560Q33723943-9F77B9E2-76B0-4368-98BC-E838F593E2C6Q33726132-F6A894A0-CB26-4E71-977D-D7CF0D2C5D29Q33735938-5C13737E-B297-4F5E-8ADF-E400864A1744Q33759821-723DEDD2-ECCA-4FC9-855A-8FB9D8F4CE3EQ33812093-C92B77D5-4A3C-4A4D-8F0C-F7DD92E6A6E1Q33856080-4CAD5E19-4FA1-44BE-901F-ABFB9C5BC13FQ33959926-45BA2779-2062-46DE-8893-573241054F6FQ34019069-79639EEE-407C-4F57-BB90-5C6F162EDB95Q34062015-05E5B027-9EE2-4AAA-967A-7DA51FABD4A4Q34324817-FF14B11C-9420-456B-8049-E807A2663ACDQ34565594-DF383072-576F-4405-BBE6-23A4E8735C87Q34630452-22000561-E22D-45FA-95C3-CB7BC4D1A45EQ34851822-C6A01400-5174-4E40-AA51-5F3D2A4D5161Q35159993-799EC47C-DDFE-4A64-AAA9-E33F107CA165Q35479955-526E6375-B0EA-4F05-B371-88B3B0B9944EQ35897548-F2CAFCD3-6C8B-4B06-986F-D41D0BDF8845Q36118514-E1462760-7C51-41D1-BE3E-4345B0BDC8EDQ36182377-6A9C2C26-FE8E-4F27-BDC5-806D7EC27B8DQ36276804-13CA0902-3F08-40EB-9C28-929BFE1866FDQ36436224-5EAA58F3-2B2B-4271-A20D-2FB9F7C9AB6AQ36478676-FD2AFDA1-5E67-4A2E-B357-37DD999DC7FFQ36502062-C7D45EEB-6803-440D-9598-F5A9148D4C8FQ36518032-A3768994-8AE2-4501-B980-D98722CFC381Q36603206-97D48A9F-46EF-40D9-AB19-36AF2BFC1A26
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
PAI-1 and atherothrombosis.
@ast
PAI-1 and atherothrombosis.
@en
type
label
PAI-1 and atherothrombosis.
@ast
PAI-1 and atherothrombosis.
@en
prefLabel
PAI-1 and atherothrombosis.
@ast
PAI-1 and atherothrombosis.
@en
P2860
P1476
PAI-1 and atherothrombosis.
@en
P2093
Vaughan DE
P2860
P304
P356
10.1111/J.1538-7836.2005.01420.X
P577
2005-08-01T00:00:00Z